Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
Authors
Keywords
-
Journal
World Journal of Gastrointestinal Oncology
Volume 12, Issue 11, Pages 1346-1363
Publisher
Baishideng Publishing Group Inc.
Online
2020-11-11
DOI
10.4251/wjgo.v12.i11.1346
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
- (2019) Hyun Cheol Chung et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
- (2019) Yung-Jue Bang et al. Gastric Cancer
- Recent advances in gastric cancer early diagnosis
- (2019) Laura Necula et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Camrelizumab: First Global Approval
- (2019) Anthony Markham et al. DRUGS
- Review: Gastric cancer—Clinical aspects
- (2019) Marino Venerito et al. HELICOBACTER
- Combination therapy with PD-1 or PD-L1 inhibitors for cancer
- (2019) Hidetoshi Hayashi et al. International Journal of Clinical Oncology
- Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
- (2019) Roy S Herbst et al. LANCET ONCOLOGY
- Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
- (2019) Ronan J. Kelly et al. CLINICAL CANCER RESEARCH
- A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
- (2019) Li-Tzong Chen et al. Gastric Cancer
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
- (2018) Y -J Bang et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
- (2018) Fatemeh K. Dermani et al. JOURNAL OF CELLULAR PHYSIOLOGY
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
- (2018) Lola Fashoyin‐Aje et al. ONCOLOGIST
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
- (2018) N Boku et al. ANNALS OF ONCOLOGY
- Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
- (2018) Toshihiko Doi et al. Gastric Cancer
- Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
- (2018) Manish A. Shah et al. JAMA Oncology
- Global patterns and trends in stomach cancer incidence: Age, period and birth cohort analysis
- (2017) Ganfeng Luo et al. INTERNATIONAL JOURNAL OF CANCER
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
- (2017) Florie Bertrand et al. Nature Communications
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Gastroesophageal Cancers: Progress and Problems
- (2017) Jaffer A. Ajani Journal of the National Comprehensive Cancer Network
- PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
- (2017) Lihu Gu et al. PLoS One
- Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability
- (2016) Changqing Ma et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology
- (2016) Jaffer A. Ajani et al. Journal of the National Comprehensive Cancer Network
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- PD-1 and its ligands are important immune checkpoints in cancer
- (2016) Yinan Dong et al. Oncotarget
- The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients
- (2016) Minghui Zhang et al. Scientific Reports
- Novel targets in the treatment of advanced gastric cancer: a perspective review
- (2016) Elisa Fontana et al. Therapeutic Advances in Medical Oncology
- Immunotherapy for Gastroesophageal Cancer
- (2016) Emily Goode et al. Journal of Clinical Medicine
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features
- (2015) Yves Dittmar World Journal of Gastrointestinal Oncology
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Clinical epidemiology of gastric cancer
- (2014) TL Ang et al. SINGAPORE MEDICAL JOURNAL
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- (2013) Hugo E R Ford et al. LANCET ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
- (2010) David Moher et al. International Journal of Surgery
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started